Genome&Company

At a glance

Genome&Company filed 70 disclosures in the last 12 months, including 7 5% holder, 5 insider and 3 issuance. The most recent key filing was on Aug 21.

Revenue for 2025 was ₩24.6B, down 11.4% on 2024. It made an operating loss of ₩29.2B. Debt was 27% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩12B and operating loss of ₩14.1B.

The 2025 annual report lists 96 employees with an average tenure of 3.4 years and average pay of ₩60.8M, #933 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩128M each on average. It paid no cash dividend for 2025. 박한수 and related parties held 14.58% at year end.

From the 2025 annual report

Staff: 96 (31 men, 65 women), of whom 3 on fixed-term contracts. Total pay for the year: ₩5.7B. Directors and auditors: 7, paid ₩895M in total.

No cash dividend was paid for 2025.

Largest shareholder

박한수 holds 7.51%; with 5 related parties the group holds 14.58% of common shares at year end (from 19.54% at the start of the year).

Auditor: 태성회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary